Britain and America have signed a key trade agreement that will maintain zero duties on British pharmaceutical exports going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost spending on drugs through the National Health Service (NHS). This pledge ensures that import taxes on these vital exports will stay at nothing for a period of 36 months.
This deal is in response to recent threats to hike tariffs on patented pharmaceutical imports, with increases discussed reaching double the cost.
"This agreement with the UK strengthens the global environment for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest exports to the United States, which is by far the largest market for major companies like GSK and AstraZeneca.
Export figures reveal that in the year to the end of the third quarter, the UK sold drugs worth £11.1bn to the US. This value made up nearly one-fifth of all goods exports in that span.
"This agreement protects jobs, stimulates investment and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The agreement entails several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum manufacturers must return to the NHS to control costs will be capped at fifteen percent. In the past, repayments were more than 20%.
Broader Context
This agreement comes amid a ongoing tension between the drug companies and the UK government over drug pricing and regulatory access.
This friction were exacerbated by claims that American patients were charged several times more for the same drugs than people in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the previous ten-year period.
